Neuroblastoma arises from the embryonal neural crest secondary to a block in differentiation.
Introduction
Neuroblastoma arises from residual immature neural crest cells within the peripheral sympathetic ganglia of very young children (1) . The clinical and biological behavior of this tumor is extremely heterogeneous, encompassing fatal tumor progression, as well as spontaneous regression and differentiation into mature ganglioneuroma. Furthermore, the degree of neuronal tumor differentiation strongly affects patient outcome. Studies from transgenic mouse models of NB with targeted overexpression of the MYCN oncogene also demonstrate that blocked neural crest differentiation leads to the malignant transformation of neuroectodermal precursors into NB (2) . Efforts to define the mechanism(s) for this blockage in neuroblast differentiation have been the focus of major research efforts over the past years, and have led to the incorporation of several differentiation strategies into neuroblastoma treatment. Retinoic acid (RA) therapy is an important component of treatment for residual disease of stage IV neuroblastoma after multimodal therapy (3) . Nevertheless, arising resistance and treatment toxicity represent relevant limiting factors and overall response rate to RA in neuroblastoma patients is low, suggesting that only a subgroup of patients benefits from the treatment. Therefore, a better understanding of the molecular mechanisms which restrict neuroblastoma differentiation could lead to improved therapeutic approaches for this highly aggressive malignancy.
Alterations in components of the transcriptional machinery and chromatin modifier genes are now associated with initiation and differentiation of multiple cancers (4) including neuroblastoma (5) . A role for epigenetics in tumorigenesis is further supported by recent genome-wide sequencing studies revealing recurrent cancer associated mutations in key epigenetic regulator genes, including histone modifiers, histone chaperones and DNA methylation modifiers (6) . In particular, methylation of histone H3 at position lysine 9 (H3K9)
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Author Manuscript Published OnlineFirst on December 12, 2013; DOI: 10.1158/0008-5472.CAN- has been extensively studied as a major factor regulating transition between transcriptionally active euchromatin and inactive heterochromatin (7) . In addition, H3K9 histone methyltransferases interact with DNA methyltransferases (e.g. DNMT1/3b) to indirectly modulate gene silencing through DNA methylation (8) . The histone modifiers EZH2 (9) and LSD1 (10) are deregulated in neuroblastoma with high expression conferring worse prognosis. In addition, repression of the tumor suppressor and chromatin modifier CHD5 through loss of heterozygosity and DNA methylation negatively correlates with long term survival (11) .
CHAF1A (CAF p150) is a primary component of the chromatin assembly factor 1 (CAF-1), composed of p150, p60, and p48 subunits, which promotes rapid assembly of nucleosomes on newly replicated DNA (12) . The importance of CHAF1A in cancer pathogenesis is supported by the finding that its overexpression has been linked to tumor progression (13), cancer susceptibility (14) , and more recently, epigenetic silencing (15) . In addition, CHAF1A
participates in a complex with MBD1 and SETDB1 during initiation of a gene silencing program by promoting H3K9 tri-methylation, heterochromatin formation, and DNA methylation (16) .
We show here that CHAF1A restricts neuroblastoma differentiation using both in vitro and in vivo orthotopic models. Elevated expression of CHAF1A indeed strongly correlates clinically with an undifferentiated neuroblastoma phenotype and poor overall survival. We also demonstrate that CHAF1A promotes oncogenic signaling pathways (including RAS, AKT, BMI1 and WNT) as well as alters glycolytic metabolism pathways. Together, these data support a novel function for the histone modifier CHAF1A restricting neural crest differentiation and promoting neuroblastoma tumorigenesis.
Research. ShRNA constructs and Antibodies: For p53 shRNA, second generation lentiviruses expressing shp53 and shLuc control were used as described (21) . To knock down CHAF1A, expression a TRIPZ lentiviral inducible shRNAmir with Tet-inducible promoter was used (Open Biosystems).
The TRE promoter drives also the expression of a TurboRFP reporter. To repress CHAF1A expression, doxycycline was added at a final concentration of 1ug ml -1 . Control lines using scrambled shRNAmir were also generated. A GIPZ lentiviral stable shRNA (Open Biosystems) was instead used to transduce neuroblastoma lines for in vivo studies. Briefly, 293T cells were transfected with pLSLPw, TRIPZ and GIPZ constructs along with packaging plasmids, pVSVG and pLV-CMV-delta 8.2 by using lipofectamine. Virus-containing supernatants were collected at 48 and 72 hours and neuroblastoma cells transduced in the presence of 8 mg/ml polybrene (Sigma). CHAF1A rabbit monoclonal antibodies (Epitomics, #5464-1) (1:500 dilution) and p53 mouse monoclonal antibodies (Sigma, #P6874) (1:1000 dilution) were used for Western Blotting. Anti-H3K9me3 antibodies were used at a dilution 1:1000 after acid extraction of the histones.
Xenograft Model: Orthotopic xenografts of human neuroblastoma were generated as described Fold Change ≥ 2. For each time point, genes were ranked with respect to the average expression change upon CHAF1A knock down. GSEA was then performed for each of the three time points using gene permutation alternative (24) . Gene Set Enrichment Analysis software v2.0.1 was used for the analysis. Default parameters were used and gene sets that met the FDR ≤ 0.25 criterion were ranked by nominal P value. Gene Ontology analysis was performed as described using the DAVID bioinformatic database (25) . 
Results

CHAF1A is repressed by p53 and highly expressed in undifferentiated neuroblastoma.
Neuroblastoma is primarily a p53 wild type malignancy and as part of previous efforts to profile the p53 transcriptional response of neuroblastoma, we observed that increased p53 levels correlated with decreased CHAF1A expression. As repression of p53 functions is critical to neuroblastoma tumorigenesis, and CHAF1A expression is altered in other malignancies, we proceeded to further analyze CHAF1A function in neuroblastoma.
Prognostic factors for neuroblastoma include age, stage at diagnosis, histology and specific genetic alterations including MYCN amplification/overexpression. We first analyzed the prognostic value of CHAF1A in a clinical cohort of 88 neuroblastoma patients (discovery set 1) using the R2 microarray database and showed that increased CHAF1A expression strongly correlates with poor overall survival (OS p<0.0001) (Figure 1a ) and higher stage of disease (Figure 1b) . In addition, multivariate logistic regression analysis showed that CHAF1A expression level is able to predict survival, independently of MYCN status (amplified versus nonamplified), age at diagnosis (< or >12 months), and stage (stage 4 versus other stages) with a hazard ratio of 2.37 and 2.22 for OS and EFS respectively (p<0.05 and p<0.005) (Table1).
Research. To confirm the regulation of CHAF1A by p53 activity, CHAF1A gene expression was assessed in multiple p53 wild type neuroblastoma lines treated with the MDM2 inhibitor, Nutlin-3a.
Quantitative RT-PCR demonstrated significant repression of CHAF1A expression upon treatment (p<0.005). However, this effect is totally abrogated in neuroblastoma p53 mutant (LAN1) or p53 knock down (LAN5 si p53) cells, confirming that CHAF1A repression is indeed p53-mediated (Figure 1c and Figure 1d ).
CHAF1A silencing promotes neuroblastoma differentiation in vitro.
To assess the biological function of CHAF1A in neuroblastoma, we first generated multiple neuroblastoma cell lines with inducible shRNA-mediated CHAF1A knockdown using a Tet-On conditional system that co-expressed RFP. We found that silencing of CHAF1A leads to a distinct morphologic change consistent with the morphologic change observed upon retinoic acid at position lysine 9, we examined the global H3K9me3 levels and found that silencing of CHAF1A significantly reduces the level of global H3K9me3 in IMR32 cells (Figure 3b) .
To further determine the role of CHAF1A as an inhibitor of differentiation, we evaluated CHAF1A expression levels in neuroblastoma cells treated with retinoic acid. In all three lines tested (LAN5, CHLA255 and NGP), the morphological differentiation (Supplementary Figure   2) is associated with a significant (p<0.005) down-regulation of CHAF1A expression levels after 7-10 days of RA treatment (Figure 3c) . Lastly, we compared the expression of CHAF1A in a small cohort of less aggressive ganglioneuroblastoma (GNB, n=11) with more aggressive, undifferentiated neuroblastoma samples (NB, n=53) (discovery set 3) (18). As shown in Figure   3d , CHAF1A expression is significantly (p<0.05) higher in the undifferentiated neuroblastoma group.
CHAF1A promotes tumorigenesis and opposes differentiation in vivo.
We then generated neuroblastoma lines with stable CHAF1A knockdown and found that CHAF1A silencing markedly inhibited in vitro proliferation of LAN5 and IMR32 neuroblastoma cell lines by day 4 (MTT assay, Supplementary Figure 3) . To assess the role of CHAF1A in promoting tumorigenesis, loss-of-function studies using three distinct neuroblastoma cell lines (LAN-5, IMR-32 and NGP) with stable CHAF1A knock down were performed in vivo in an orthotopic neuroblastoma model (sub-renal capsule injection). This model closely recapitulates the highly angiogenic and invasive growth characteristics of undifferentiated human neuroblastoma (27) . We found that CHAF1A silencing significantly reduces tumor growth in all the three cell lines tested (Figure 4a and 4b) 
appeared less vascular and Western Blotting analysis suggested that tumor growth is proportional to CHAF1A levels (Supplementary Figure 4) . 
CHAF1A silencing induces neuronal differentiation pathways and inhibits major oncogenic pathways.
In order to unveil changes in gene expression associated with changes in neuroblastoma phenotype induced by CHAF1A, we performed gene expression profiling (Affymetrix U133+2.0 arrays) in IMR32 cells five and ten days after CHAF1A silencing. Clustered heat map of the differentially expressed genes is shown in Figure 5a (GEO series accession number GSE51978).
We then examined the occurrence of Gene Ontology (GO) terms of genes associated with changes in CHAF1A expression using the DAVID online analysis platform (28) . Notably, the most significantly enriched functional categories (p-value<0.05) upon CHAF1A silencing are associated with multiple processes involved in neuronal differentiation (axonogenesis, synaptic transmission, cell-cell signaling, catecholamine biosynthesis and nervous system development) ( Table 2) , validating CHAF1A as a potential critical regulator of neuronal differentiation.
Furthermore, these functional categories were distinct from the ones described to be enriched in neuroblastoma cell differentiation upon Cyclin D1 and Cdk4 silencing (29) or retinoic acid treatment (30), suggesting a distinctive mechanism for CHAF1A in inducing cell differentiation (Supplementary Table 1 and Supplementary Table 2 ).
In addition, Gene Set Enrichment Analysis (GSEA) revealed that genes regulated by CHAF1A
were associated with major metabolic and oncogenic pathways. CHAF1A silencing significantly enriches for cell metabolism pathways (valine, leucine, and isoleucine degradation, glutamate metabolism and insulin pathways) (Figure 5b ) and suppresses pathways with known oncogenic function in neuroblastoma (KRAS, ALK, AKT, and BMI1) (nominal p-value <0.05 and FDR qvalue <0.25) (Figure 5c) . A complete list of the significant pathways is shown in Supplementary Table 3 . Quantitative RT-PCR confirmed that CHAF1A affects the expression of selected metabolic genes with important roles in insulin, type 2 diabetes, valine, leucine, and isoleucine degradation pathways both in IMR32 and LAN5 cells. Notably, DHRS2, an enzyme with crucial oxidoreductase activities, is markedly upregulated upon CHAF1A silencing (Figure   5d ).
In summary, we demonstrate that the expression of CHAF1A is regulated by p53 and positively correlates with a more un-differentiated aggressive neuroblastoma phenotype in vitro and in vivo.
In addition, silencing of CHAF1A leads to up-regulation of genes controlling neuronal differentiation, normalized glucose metabolism, as well as down-regulation of major oncogenic pathways. As discussed below, these data suggest that CHAF1A or downstream pathways may represent novel therapeutic targets which could sensitize neuroblastoma to differentiation in vivo. Mirroring the clinical observations, using an orthotopic xenograft model of neuroblastoma we show that CHAF1A expression drives a more undifferentiated neuroblastoma phenotype in vivo.
Suppression of CHAF1A strongly induces neuroblastoma to differentiate, suggesting that CHAF1A restricts innate differentiation pathways and may modulate resistance to differentiation-based therapies. Of note, we present gene expression data suggesting that CHAF1A may act through mechanisms independent of previously characterized Cyclin D1/ Cdk4 or retinoic acid driven pathways (Supplementary Tables 1 and 2 ). However, neuroblastoma differentiation is a complex and poorly understood process involving multiple networks of genetic and epigenetic pathways. Understanding the regulatory mechanisms of neuroblastoma differentiation is important for obtaining insight into basic biology and for developing novel therapies that may overcome the resistance to retinoids.
Epigenetic changes including histone modifications play a central role in controlling differentiation and defining the pluripotent state of embryonic and cancer stem cells (34) . Recent comprehensive genome wide studies define distinct patterns of histone modifications and DNA methylation during multilineage differentiation of stem cells (35, 36) . These and other studies point to a complex interaction of DNA histone modifications and DNA methylation controlling cellular differentiation barriers (37) and disruption of these epigenetic mechanisms is strongly implicated in tumorigenesis and survival of cancer stem populations (38) . H3K9 tri-methylation has been characterized as a major factor regulating transitions between transcriptionally active euchromatin and inactive heterochromatin (39) . Binding of UHRF1 to methylated H3K9 is required for DNA methylation maintenance (8) . Methylated H3K9 serves as a binding platform for heterochromatin protein 1 (HP1) which directs DNMT1-dependent DNA methylation (40).
Of note, previous studies demonstrate that CHAF1A acts independently of CAF1 as an epigenetic silencing factor (15) regulating H3K9me3 epigenetic marking of heterochromatin domains in pluripotent embryonic cells (41) . CHAF1A also modulates DNA methylation, forming a complex with MBD1 and SETDB1 and modulating DNA methylation (16) . 
multiple tumor suppressor genes in neuroblastoma (9) and genome-wide DNA methylation studies identified candidate DNA methylation markers with important prognostic value in neuroblastoma (44) . Lastly, the definition of the roles of novel chromatin regulators in neuroblastoma, such as CHD5, highlights the importance of these histone posttranslational modifications in controlling gene expression during neuronal differentiation (45) .
In further support of an oncogenic role of CHAF1A, our GSEA analysis demonstrates that RAS as well as AKT, BMI and ALK pathways are strongly repressed upon CHAF1A knockdown (Figure 5 and Supplementary Table 3 ). Ras signaling networks drive cellular proliferation and restrict differentiation and previous studies have also suggested a role for RAS-MEK signaling in regulation of responses to retinoic acid in different cellular systems (46) . Activation of NRAS appears to be critical in neuroblastoma tumorigenesis, considering its function in stabilizing MYCN, promoting MYCN-dependent cell cycle progression, and blocking p53-mediated cell cycle check points and pro-apoptotic effects (22, 47) .
In addition, bioinformatic analyses of gene expression changes also suggest that CHAF1A may alter metabolic pathways to promote the Warburg effect (increased glucose consumption and decreased oxidative phosphorylation). The most enriched KEGG and Biocarta pathways after CHAF1A knock down were pathways involved in cell metabolism (valine leucine and isoleucine degradation and glutamate metabolism among others, Figure 5 and Supplementary Table 3 
